Lipid peroxidation and antioxidant defense in chronic atrophic gastritis associated with Helicobacter pylori

DOI: https://doi.org/10.29296/25877305-2019-11-08
Download full text PDF
Issue: 
11
Year: 
2019

O. Smirnova(1), MD; Professor V. Tsukanov(1), MD; A. Sinyakov(1), Candidate of Biological Sciences; O. Moskalenko(1), Candidate of Biological Sciences; N. Elmanova(1); E. Ovcharenko(1); N. Titova(2), Candidate of Biological Sciences 1-Research Institute for Medical Problems of the North, Federal Research Center «Krasnoyarsk Research Center, Siberian Branch, Russian Academy of Sciences», Krasnoyarsk 2-Siberian Federal University, Krasnoyarsk

Chronic atrophic gastritis (CAG) is a precancerous disease of the stomach. According to Correa’s cascade, atrophic gastritis associated with Helicobacter pylori (Hp) can contribute not only to the occurrence, but also to the progression of metaplasia, dysplasia in the epithelial cells of the gastric mucosa, and to the transformation of these changes into gastric cancer. The risk of developing cancer increases by 15 times in CAG. Lipid peroxidation (LPO) is a process of oxidative degradation of lipids by free radicals. The results of LPO are balanced by the antioxidant defense (AOD) system. The objective of the investigation was to study LPO-AOD values in Hp-associated CAG.
Keywords: 
gastroenterology
oncology
lipid peroxidation
antioxidant defense
chronic atrophic gastritis
Helicobacter pylori
stomach cancer

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Bordin D.S., Masharova A.A., Homeriki S.G. Hronicheskij gastrit: sovremennyj vzgljad na staruju problemu // Eksperim. i klin. gastroenterol. – 2012; 5: 99–106 [Bordin D.S., Masharova A.A., Homeriki S.G. Chronic gastritis: a modern look at the old problem // Eksperim. i klin. gastroenterol. – 2012; 5: 99–106 (in Russ.)] URL: https://cyberleninka.ru/article/v/hronicheskiy-gastrit-sovremennyy-vzglyad-na-staruyu-problemu
  2. Vernigorodskij S.V. Osobennosti strukturnyh izmenenij slizistoj obolochki zheludka pri hronicheskom gastrite u lits raznyh vozrastnyh grupp // Klin. i eksperim. morfol. – 2014; 1 (9): 4–7 [Vernygorodskyi S.V. Features of structural changes of the gastric mucosa of different age groupS patients in hronic gastritis // Klin. i eksperim. morfol. – 2014; 1 (9): 4–7 (in Russ.)].
  3. Volkova N.N. Faktory riska razvitija hronicheskogo atroficheskogo gastrita (literaturnyj obzor) // Rus. med. zhurn. – 2013; 21 (31): 1617–20 [Volkova N.N. Faktory riska razvitiya khronicheskogo atroficheskogo gastrita (literaturnyi obzor) // Rus. med. zhurn. – 2013; 21 (31): 1617–20 (in Russ.)].
  4. Lazebnik L.B., Vasil'ev Ju.V., Scherbakov P.L. i dr. Helicobacter pylori: rasprostranennost', diagnostika, lechenie // Eksperim. i klin. gastroenterol. – 2010; 2: 3–7 [Lazebnik L.B., Vasil’ev Yu.V., Shcherbakov P.L. et al. Helicobacter pylori: rasprostranennost’, diagnostika, lechenie // Eksperim. i klin. gastroenterol. – 2010; 2: 3–7 (in Russ.)].
  5. Smirnova O.V., Titova N.M., Elmanova N.G. Osobennosti prooksidantnoj i antioksidantnoj sistemy u bol'nyh mnozhestvennoj mielomoj v zavisimosti ot stadii zabolevanija // Bjull. eksperim. biologii i meditsiny. – 2014; 157 (3): 357–61 [Smirnova O.V., Elmanova N.G., Titova N.M. The relationship between the pro-oxidant and antioxidant system status of patients with multiple myeloma and the disease stage // Bulletin of Experimental Biology and Medicine. – 2014; 157 (3): 375–9)].
  6. Smirnova O.V., Titova N.M., Manchuk V.T. i dr. Osobennosti tsitokinovoj reguljatsii u bol'nyh mehanicheskoj zheltuhoj razlichnogo geneza // Sovremennye problemy nauki i obrazovanija. – 2015; 4: 425 [Smirnova O.V., Titova N.M., Manchuk V.T. et al. Cytokine regulation in patients with obstructive jaundice various genesis // Sovremennye problemy nauki i obrazovaniya. – 2015; 4: 425 (in Russ.)].
  7. Pavlovich I.M., Gordienko A.V., Batskov S.S. i dr. Vlijanie Helicobacter pylori na morfologicheskoe sostojanie slizistoj obolochki zheludka pri hronicheskom gastrite// Mediko- biologicheskie i sotsial'no-psihologicheskie problemy bezopasnosti v chrezvychajnyh situatsijah. – 2013; 2: 32–5 [Pavlovich I.M., Gordienko A.V., Batskov S.S. et al. Effect of Helicobacter pylori on the morphological status of the gastric mucosa in chronic gastritis // Medico-Biological and Socio-Psychological Problems of Safety in Emergency Situations. – 2013; 2: 32–5 (in Russ.)]. https://doi.org/10.25016/2541-7487-2013-0-2-58-65.
  8. Skvortsov V.V., Skvortsova E.M. Aktual'nye voprosy diagnostiki i lechenija antral'nogo gastrita tipa // Poliklinika. – 2012; 1.1: 102–6 [Skvortsov V.V., Skvortsova E.M. Aktual’nye voprosy diagnostiki i lecheniya antral’nogo gastrita tipa // Poliklinika. – 2012; 1.1: 102–6 (in Russ.)].
  9. Stepanov Ju.M., Simonova E.V. Povyshenie informativnosti endoskopicheskoj diagnostiki predrakovyh izmenenij i raka zheludka u bol'nyh s atroficheskim gastritom // Gastroenterologija. – 2013; 4 (50): 23–33 [Stepanov Yu.M., Simonova Ye.V. Increase of informativeness of endoscopic diagnosis for precancerous changes and gastric cancer in patients with atrophic gastritis // Gastroenterologiya. – 2013; 4 (50): 23–33 (in Russ.)].
  10. Adamu M., Weck M., Rothenbacher D. et al. Incidence and risk factors for the development of chronic atrophic gastritis: five year follow up of a population based cohort study // Int. J. Cancer. – 2011; 128: 1652–8.
  11. Alakkari A., Zullo A., O’Connor H. Helicobacter pylori and Nonmalignant Diseases // Helicobacter. – 2011; 16 (1): 33–7. DOI: 10.1111/j.1523-5378.2011.00878.x.
  12. Correa P. Gastric cancer: overview // Gastroenterol. Clin. North. Am. – 2013; 42 (2): 211–7. DOI: 10.1016/j.gtc.2013.01.002.
  13. Dinis-Ribeiro M., Areia M., de Vries A. et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) // Endoscopy. – 2012; 44 (1): 74–94. http://dx.doi.org/10.1055/s-0031-1291491.
  14. Graham D. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits // Gastroenterology. – 2015; 148 (4): 719–31. DOI: 10.1053/j.gastro.2015.01.040.
  15. Hunt R., Xiao S., Megraud F.et al. Helicobacter Pylori in developing countries. World Gastroenterology Organisation Global Guideline // J. Gastrointestin. Liver Dis. – 2011; 20 (3): 299–304.
  16. Lee Y., Chen T., Chiu H. et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention // Gut. – 2013; 62 (5): 676–82. DOI: 10.1136/gutjnl-2012-302240.
  17. Tonkic A., Tonkic M., Lehours P. et. al. Epidemiology and diagnosis of Helicobacter pylori infection // Helicobacter. – 2012; 17 (1): 1–8. DOI: 10.1111/j.1523-5378.2012.00975.x.
  18. Wang J., Xu L., Shi R. et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis // Digestion. – 2011; 83 (4): 253–60. DOI: 10.1159/000280318.
  19. Watari J., Chen N., Amenta P. et al. Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development // World J. Gastroenterol. – 2014; 20 (18): 5461–73. DOI: 10.3748/wjg.v20.i18.5461.
  20. Yoshida T. et al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer // Int. J. Cancer. – 2014; 134 (6): 1445–57. DOI: 10.1002/ijc.28470.